Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accumulated Expenses (2016 - 2022)

Historic Accumulated Expenses for Cumberland Pharmaceuticals (CPIX) over the last 13 years, with Q4 2022 value amounting to $17.6 million.

  • Cumberland Pharmaceuticals' Accumulated Expenses rose 10289.91% to $17.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $17.6 million, marking a year-over-year increase of 10289.91%. This contributed to the annual value of $17.6 million for FY2022, which is 10289.91% up from last year.
  • As of Q4 2022, Cumberland Pharmaceuticals' Accumulated Expenses stood at $17.6 million, which was up 10289.91% from $8.7 million recorded in Q4 2021.
  • In the past 5 years, Cumberland Pharmaceuticals' Accumulated Expenses ranged from a high of $17.6 million in Q4 2022 and a low of $8.7 million during Q4 2021
  • For the 5-year period, Cumberland Pharmaceuticals' Accumulated Expenses averaged around $13.1 million, with its median value being $11.3 million (2020).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first plummeted by 3366.69% in 2019, then soared by 10289.91% in 2022.
  • Cumberland Pharmaceuticals' Accumulated Expenses (Quarter) stood at $16.7 million in 2018, then crashed by 33.67% to $11.1 million in 2019, then rose by 1.53% to $11.3 million in 2020, then dropped by 22.98% to $8.7 million in 2021, then soared by 102.9% to $17.6 million in 2022.
  • Its Accumulated Expenses was $17.6 million in Q4 2022, compared to $8.7 million in Q4 2021 and $11.3 million in Q4 2020.